DPS-2: A Novel Dual MEK/ERK and PI3K/AKT Pathway Inhibitor with Powerful Ex Vivo and In Vivo Anticancer Properties

Abstract

Development of novel bioactive compounds against KRAS and/or BRAF mutant colorectal cancer (CRC) is currently an urgent need in oncology. In addition, single or multitarget kinase inhibitors against MEK/ERK and PI3K/AKT pathways are of potential therapeutic advantage. A new compound based on the benzothiophene nucleus was synthesized, based on previous important outcomes on other pharmaceutical preparations, to be tested as potential anticancer agent. Treatments by 2-5 μM DPS-2 of several CRC and melanoma cell lines bearing either BRAF or KRAS mutations have shown a remarkable effect on cell viability in 2D and 3D cultures. More detailed analysis has shown that DPS-2 can kill cancer cells by apoptosis, reducing at the same time their autophagy properties. After testing activities of several signaling pathways, the compound was found to have a dual inhibition of two major proliferative/survival pathways, MEK/ERK and PI3K/AKT, in both CRC and melanoma, thus providing a mechanistic evidence for its potent anticancer activity. Antitumor activity of DPS-2 was further validated in vivo, as DPS-2 treatment of mouse xenografts of Colo-205 colorectal cancer cells remarkably reduced their tumor formation properties. Our findings suggest that DPS-2 has significant anti-KRAS/anti-BRAF mutant CRC activity in preclinical models, potentially providing a novel treatment strategy for these difficult-to-treat tumors, which needs to be further exploited.

Introduction

Colon cancer (CRC) is the fourth leading cause of cancer deaths worldwide. It results from the accumulation of multiple genetic and epigenetic alterations, leading to the transformation of colon epithelial cells into invasive adenocarcinomas [1]. Increasing knowledge of the major signaling pathways and molecular defects involved in colon carcinogenesis has led to the development of several novel target-based therapeutics, which have given encouraging results in patient outcome. Metastatic melanoma is also one of the most dangerous types of tumors. Within the most crucial pathways that become deregulated in these cancers belong the ERK/MAPK, JAK-STAT, PI3K/AKT/mTOR, and Wnt pathways [2–4]. The Ras/Raf/MEK/ERK mitogen-activated protein kinase (ERK/MAPK) signaling pathway, involved in normal cell proliferation and survival, plays a critical role in colorectal and melanoma cancer progression since activating mutations of key genes like RAS and BRAF lead to constitutive activation of the pathway, resulting in increased proliferation and tumor formation [5,6].

BRAF kinase, a key component of the ERK/MAPK signaling cascade, was found mutated in a variety of cancers [7]. Vemurafenib (PLX4032, Zelboraf) and dabrafenib are the most effective
BRAFV600E selective inhibitors and approved drugs for the treatment of BRAFV600E melanoma [8–10]. BRAFV600E mutant colorectal cancers are nonresponsive to its action due to, among other reasons, a feedback activation of EGFR [11–13]. Thus, combined treatment including BRAF and EGFR inhibition is shown to be of potent benefit for BRAF mutant colon cancer patients [14,15].

Other preclinical and/or therapeutic approaches regarding the ERK/MAPK signaling pathway include the use of MEK or even ERK inhibitors, which also offer the advantage of targeting this pathway in patients with either RAS or BRAF mutations [16–18]. Furthermore, combinations of BRAF and MEK inhibitors have come up with some encouraging results in clinical trials involving BRAF mutant colorectal cancer patients [19]. Combinations of MEK/ERK with PI3K/AKT pathway inhibitors have shown very promising preclinical and clinical efficiency. Upregulation of the PI3K/AKT pathway occurs in approximately 60% of CRC cases, which renders AKT a potential target for inhibition. Halilovic et al. observed increased antitumor activity with combined MEK and AKT inhibition in KRAS/PI3KCA-double-mutant HCT15. Mutant HCT15 tumor xenografts were treated with the MEK inhibitor PD0325901 and AKTi-1/2 alone or in combination [20]. Treatment with either agent alone had no significant effect on tumor growth; however, combined treatment abrogated the growth of tumor xenografts.

The existing therapies for the treatment of metastatic colorectal cancer include either antiangiogenic agents, like bevacizumab and ramucirumab that target VEGF-A and VEGFR, respectively, or anti-EGFR antibodies, with a limitation of only K-RAS wild-type patients, like cetuximab or panitumumab, in combination with chemotherapy drugs like irinotecan, FOLFIRI, or FOLFOX [21–24]. Furthermore, since colorectal cancer is a highly heterogeneous disease with a set of different pathways involved in its development and progression, there are an increasing number of potent targets for therapy. Consequently, multikinase inhibitors, like the FDA-approved regorafenib and more under development, could be a therapeutic perspective for colorectal cancer and melanoma patients with a broader range of mutations.

Focusing on colorectal cancer, the absence of efficient drug treatments against KRAS- and BRAF- mutant tumors makes the development of new therapeutic agents an urgent need.

Benzothiophene compounds of the general formula, depicted in Figure 1, have been previously described as useful medications for the treatment of various medical indications associated with postmenopausal syndrome, uterine fibroid disease, endometriosis, and aortal smooth muscle cell proliferation (US005484798A). Virtually all of the known bioactive substances, which refers to the process of finding new uses of existing compounds outside the scope of original indication.

This study was designed to test the hypothesis that DPS-2 (Figure 1), a newly synthesized small molecule, can act as a novel dual MEK-ERK and PI3K-AKT pathway inhibitor coupled with potent antitumor properties in CRC and melanoma, both in cancer cell and in animal models. Notably, this agent has a significant apoptotic efficacy against mutant KRAS and BRAF cancer cells and tumors both in vitro and in vivo, for which specific efficient therapies are currently missing. The effect of the new compound DPS-2 on MEK/ERK and PI3K/AKT pathways known to be involved in colon cancer and melanoma progression is presented and discussed towards its potential further exploitation as an anticancer drug.

Materials and Methods

Experimental Procedures

1H NMR spectra were recorded at 300 or 600 MHz on Varian 300 or 600 spectrometer. 13C NMR spectra were recorded at 75 MHz on a Varian 300 spectrometer. 1H NMR and 13C NMR chemical shifts (δ) are reported in parts per million (ppm) relative to residual proton signals in CDCl3 (δ = 7.26, 77.16 ppm), CD3OD (δ = 4.87, 49.00 ppm), or DMSO-D6 (δ = 2.50, 39.43 ppm). Coupling constants (J) are reported in Hertz (Hz) and refer to apparent multiplicities. The following abbreviations are used for the multiplicities: singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), doublet of doublet (dd), doublet of triplet (dt), and broad (br). Melting points (m.p.) were determined on a Buchi 130 capillary melting point apparatus and are uncorrected. Mass spectra were recorded on a Thermo Fleet instrument by positive or negative electrospray ionization (ES+ or ES−). HRMS were recorded on a Thermo Velo instrument. Samples were infused in solution usually at 10–20 μl/min by means of a syringe pump. MeOH was used as solvent. TLC was carried out using Macherey-Nagel silica plates with a layer thickness of 0.25 mm SIL G-25 60 UV254. Visualization was effected with ultraviolet light and phosphomolybdic acid reagent 10% in 95% ethanol. All solvents and reagents were obtained from commercial suppliers. Tetrahydrofuran was distilled from sodium/benzophenone ketyl.

2-(3-Methoxyphenylthio)-1-(4-methoxyphenyl)ethanone

Potassium hydroxide (0.662 g 10 mmol 85% purity) was added to a recently prepared solution of ethanol/water (10 ml EtOH/4.2 ml H2O). To this solution, 3-mercaptoanisol (1) (1.402 g 10 mmol) was added, and the solution was cooled to 5°C. Then, a solution of 2-bromo-1-(4-methoxyphenyl)ethanone (2) (2.29 g 10 mmol) in ethyl acetate (6 ml) was added, and the reaction mixture was stirred at room temperature for about 18 hours. After this period, the reaction mixture was concentrated under reduced pressure, and the residue was dissolved in ethyl acetate (90 ml) and water (30 ml). The water phase was extracted with ethyl acetate (30 ml). The combined organic phases were washed with hydrochloric acid 5% (30 ml), water (30 ml), saturated solution of sodium bicarbonate (30 ml) water (30 ml), and saturated solution of sodium chloride (30 ml). After drying with anhydrous sodium sulfate, the solvent was removed in rotary evaporator. The remaining residue was recrystallized using ethyl acetate/petroleum ether to afford 2.3 g of the desired product. A

Figure 1. Chemical structure of DPS-2.
second crop of 0.15 g was obtained after a second recrystallization with ethyl acetate/hexane. Total yield 84%.

\( \text{RF (EtO\!/Pet. Ether 3:7) = 0.26 m, p 51-53°C.} \)

\( \text{1H NMR (600 MHz CDCl}_3 \)  *δ* 3.77 (s, 3H, -OCH3), 3.87 (s, 3H, -OCH3), 4.25 (s, 1H, \(-CH_2\)), 6.72-6.77 (m, 1H, ArH), 6.92-6.98 (m, 4H, ArH), 7.19 (t, 1H, ArH, J = 8.0 Hz), 7.93 (d, 2H, ArH, J = 8.9 Hz).

\( \text{13C NMR (75 MHz, CDCl}_3 \)  δ 40.85, 55.36, 55.62, 112.82, 113.95, 115.26, 124.85, 129.94, 131.13, 136.53, 159.90, 162.91, 163.91, 197.29.

**6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophene**

A round bottom flask with polyphosphoric acid (13.5 g) was heated at 85°C in oil bath under argon. To this viscous liquid was added at 85°C 2-(3-methoxyphenylthio)-1-(4-methoxyphenyl)ethanone (3) (2.2 g, 7.62 mmol) in small portions. The dark red-colored reaction mixture was stirred for 2 hours at 85°C under argon. Then, the reaction mixture was gradually cooled, and when the temperature was about 70°C, cold water and crushed ice were added slowly. After trituration with water, the dark red mixture solidified and remained in the freezer overnight. The beige solid was filtrated and added to a round-bottom flask with acetone (20 ml). The mixture was refluxed for 1 hour and then cooled in ice-bath. The off-white product was filtrated and we obtained 1.26 g of the desired product. Yield 61%.

\( \text{RF (EtO\!/Pet. Ether 2:8) = 0.46.} \)

\( \text{1H NMR (600 MHz DMSOD)  δ 3.80 (s, 3H, -OCH}_3\), 3.82 (s, 3H, -OCH}_3\), 6.95-7.05 (m, 3H, ArH), 7.53 (d, 1H, ArH, J = 1.7 Hz), 7.61 (s, 1H, ArH), 7.55-7.70 (m, 3H, ArH).} \)

**Methyl 4-(2-(piperidin-1-yl)ethoxy)benzoate (7)**

A mixture of methyl 4-hydroxybenzoate (5) (0.68 g 4 mmol) and powdered anhydrous potassium carbonate (1.3 g, 10 mmol) was heated to 100°C. Then, 1-(2-chloroethyl)piperidine hydrochloride (6) (0.99 g, 4.84 mol) was added in portion, over a period of 5 minutes. The reaction mixture was stirred at 100°C for about 3 hours. Then, the reaction was cooled at room temperature and diluted with 150 ml of ethyl acetate. The organic phase was washed with water (6×10 ml) and saturated solution of sodium chloride (1×10 ml), dried over anhydrous sodium sulfate, and evaporated in vacuo. The desired product was purified with flash column chromatography using a silica path using as eluent ethyl acetate/methanol 95:5. We received 0.99 g of a red-brown oil. Yield 84%.

\( \text{RF (MeOH/EtOAc 8:2) = 0.46.} \)

\( \text{1H NMR (300 MHz CDCl}_3 \)  δ 1.45-1.6 (m, 2H, \(-CH_2\)), 1.65-1.85 (m, 4H, \(-CH_2\)), 2.6-2.8 (m, 4H, \(-CH_2\)), 2.94 (t, 2H, \(-CH_2\)), 3.73 (s, 3H, \(-OCH}_3\), 3.86 (s, 3H, -OCH3), 4.23 (t, 2H, \(-OCH}_2\), J = 5.4 Hz), 6.74 (d, 4H, ArH, J = 8.6 Hz), 6.94 (dd, 1H, ArH, J = 8.9, 2.4 Hz), 7.28-7.37 (m, 3H, ArH), 7.50 (d, 1H, ArH, J = 8.9 Hz), 7.70-7.80 (m, 2H, ArH).

\( \text{13C NMR (75 MHz, CDCl}_3 \)  δ 23.33, 24.75, 54.75, 57.14, 65.02, 104.59, 114.18, 114.29, 114.09, 126.05, 130.35, 130.53, 130.87, 132.44, 134.01, 140.15, 142.72, 157.75, 159.84, 162.86, 193.17.

\( \text{MS-ESI  m/z 502.20 [M + H] \text{+} (calc. For C}_{30}\text{H}_{31}\text{NO}_4\text{S), 524.18 [M + Na] \text{+}.} \)

\( \text{(4-(2-(Piperidin-1-yl)ethoxy)phenyl)(6-methoxy-2-(4-methoxy-phenyl)benzo[b] thiophen-3-yl)methanol hydrochloride} \)

To a round-bottom flask were added 4-(2-(piperidin-1-yl)ethoxy)benzoic acid hydrochloride (8) (0.81 g, 2.825 mmol), chlorobenzene (9 ml), thionyl chloride (0.15 ml) and DMF (0.2 ml). The reaction mixture was stirred for 2 hours at 75°C-80°C under argon. Excess of thionyl chloride and chlorobenzene was removed by vacuum distillation. Vacuum distillation was repeated with fresh chlorobenzene (5 ml) in order to remove any remaining quantity of thionyl chloride. Then, dry methylene chloride (15 ml) was added to the residue. To the corresponding solution were added 6-methoxy-2-(4-methoxyphenyl)benzo[b]thiophene (4) (0.75 g, 2.78 mmol) and aluminum trichloride (2.3 g 24 mmol). The mixture was stirred at 27°C-29°C for 2 hours. The reaction was quenched at 5°C-10°C by adding THF (10 ml) hydrochloric acid 20%(3 ml) and water (10 ml). The aqueous phase was removed and was extracted with methylene chloride (3×20 ml). The combined organic phases were extracted with water (15 ml) dried over anhydrous sodium sulfate and evaporated under reduced pressure. The remaining oil was purified with flash column chromatography using dichloromethane/MeOH 96:4 as eluent in order to furnish 0.91 g of the desired product as a yellow oil. Yield 61%.

\( \text{RF (CHCl}_3\text{/MeOH 9:1) = 0.56.} \)

\( \text{1H NMR (300 MHz CDCl}_3 \)  δ 1.4-1.8 (m, 6H, \(-CH_2\)), 2.57 (m, 4H, \(-NC\)), 2.81 (t, 2H, \(-CH_2\)), 5.6 Hz), 3.88 (s, 3H, \text{COOCH}_3\), 4.21 (t, 2H, \(-OCH}_2\), J = 5.6 Hz) 6.95-7.05 (m, 2H, ArH), 7.90-8.00 (m, 2H, ArH).

\( \text{13C NMR (75 MHz, CDCl}_3 \)  δ 25.00, 26.47, 52.35, 55.91, 58.76, 66.69, 115.32, 123.70, 132.58, 164.13, 168.33.

**MS-ESI  m/z 48.76, 50.91, 133.76, 135.91, 163.32, 169.39.**

**6-Methoxy-2-(4-methoxyphenyl)benzo[b]thiophene**

A solution of sodium hydroxide (1.8 ml) was added, and the reaction was allowed to stir at room temperature for 24 hours. The mixture was evaporated and the residue diluted with water (30 ml). The resulting solution was cooled to 5°C and acidified with 6 N hydrochloric acid. The mixture was filtrated and the crystals were washed with cold MeOH. We received 0.95 g of a light beige product and the yield was 89%.

\( \text{RF (MeOH/EtOAc 8:2) = 0.34.} \)

\( \text{1H NMR (300 MHz DMSOD)  δ 1.4-2.15 (m, 6H, \(-CH_2\)), 3.12 (td, 2H, \(-CH_2\)), J = 13.0, 8.2 Hz), 3.25-3.4 (m, 4H, \(-NC\)), 4.49 (t, 2H, \(-OCH}_2\), J = 4.8 Hz) 7.00-7.20 (m, 2H, ArH), 7.95-8.15 (m, 2H, ArH).

\( \text{13C NMR (75 MHz, DMSOD)  δ 22.53, 24.06, 54.92, 57.02,} 63.34, 114.52, 125.34, 132.93, 162.81, 169.39.

**MS-ESI  m/z 502.22 [M + H] \text{+} (calc. For C}_{14}\text{H}_{15}\text{NO}_3\text{S).} \)
with water (10 ml) and saturated solution of sodium chloride (10 ml), dried over anhydrous sodium sulfate, and concentrated in vacuo. The residue was purified with flash column chromatography by using CHCl3/MeOH (97:3) as eluent. We obtained 0.1 g of a light yellow oil which solidified after staying in the freezer. Yield 89%. 

RF (CHCl3/MeOH 9:1) = 0.40. 

1H NMR (300 MHz CDCl3) δ 1.35-1.5 (m, 2H, -CH2-), 1.55-1.65 (m, 4H, -CH2-), 2.4-2.55 (m, 4H, -NCH2-), 2.74 (t, 2H, -CH2-CON-, J = 6 Hz), 3.82 (s, 6H, -OCH3), 4.23 (t, J = 6 Hz, 2H, -OCH2-), 6.15 (s, 1H, -HOCH), 6.75-6.85 (m, 3H, ArH), 6.87-6.97 (m, 2H, ArH), 7.27 (s, 1H, ArH), 7.30 (d, 2H, ArH, J = 8.4 Hz), 7.37-7.47 (m, 2H, ArH), 7.59 (d, 1H, ArH, J = 8.4 Hz). 

13C NMR (75 MHz, CDCl3) δ 24.01, 25.64, 54.93, 57.79, 65.64, 69.46, 69.52, 104.67, 113.80, 114.11, 114.33, 125.48, 126.19, 127.44, 130.83, 132.01, 132.54, 138.43, 138.95, 140.72, 157.09, 157.81, 159.71. 

MS-ESI m/z 504.41 [M + H]+. HRMS m/z 504.2199 [M + H]+ (calc. For C30H34NO4S 504.2203). 

Cell Lines and Treatments 

RKO, HT29, Colo-205, DLD-1, and HCT116 human colon adenocarcinoma; Caco-2 colon adenoma; NIH3T3 mouse embryonic fibroblast; and HepG2 human hepatocellular carcinoma cell lines were obtained from American Type Culture Collection. All cell lines used in this study were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), antibiotics, and amino acids (all from Life Technologies). The following day, cells were treated in 2D cultures were taken under light and confocal microscope (Leica TCS SPE confocal laser scanning microscope) after the treatment with inhibitor was applied for indicated incubation time. 

Western Blotting 

Whole cell lysates were prepared using lysis buffer. Extracts were resolved on SDS-PAGE and transferred to a nitrocellulose membrane (Whatman, Scheicher & Schuell, Dassel, Germany). Membranes were incubated with specific antibodies in an indicated dilution overnight at 4°C, washed, and incubated with the appropriate secondary antibody for 1 hour at room temperature. Primary antibodies were used against pAKT (ser473) #9271, pAKT (thr308) #9275, p-SAPK/JNK (Thr183/Tyr185) #9251, pS6R (s235/236) #2211, pMEK (s217/221) #9121, Caspase-3 #9662, and cleaved caspase-3 (Asp175) #9661 from Cell Signaling (Danvers, MA, USA); SQSTM1/p62 (sc-28,359), PARP-1 (sc-7150), pERK (s235/236) #2211, pMEK (s217/221) #9121, Caspase-3 #9662, and cleaved caspase-3 (Asp175) #9661 from Cell Signaling (Danvers, MA, USA); SQSTM1/p62 (sc-28,359), PARP-1 (sc-7150), pERK (sc-7383), p-p38 (sc-7973), Actin (sc-8432), and α-Tubulin (sc-8035) were purchased from Santa Cruz (Biotechnology, Inc., 2145 Delaware Avenue, Santa Cruz, CA 95060 USA). Purified mouse anti-RIP (610458) was obtained from BD Transduction Laboratories and RIPK3 (NB22-24588) from Novus Biologicals. Secondary antibodies were goat anti-mouse (sc-2005, Santa Cruz) and goat anti-rabbit (#111-035-003, Jackson). Antibody signal was obtained with the enhanced chemiluminescence plus Western blotting detection system (Amersham Biosciences, Uppsala, Sweden) after exposure to Kodak Super RX film. Values were measured using the Image Studio Lite 4.0 software (LI-COR Biosciences), and protein levels were normalized against tubulin or actin. Experiments were independently repeated at least two times. 

Two-Dimensional Culture 

For the 2D culture experiments, cells (5000 cells/well) were grown on coverslips in 24-well plates in medium at 37°C. Photographs of the 2D cultures were taken under light and confocal microscope (Leica TCS SPE confocal laser scanning microscope after the appropriate staining). LAS AF software was used for image 627 acquisition (Leica Lasertechnik, Heidelberg, Germany). Cells were fixed with 4% paraformaldehyde, washed with PBS, and permeabilized with 0.25% Triton. Cell cytoskeleton was stained with phalloidin (Alexa Fluor 546, A22283, Life Technologies). Nuclei were stained with Hoechst No. 33342 (Sigma, B2261) for apoptosis detection; cleaved caspase-3 marker of apoptosis was detected by cleaved caspase-3 antibody. Secondary green fluorescent anti-rabbit antibody (Alexa Fluor 488, #A11008, Invitrogen) was used against primary anti–cleaved caspase-3 antibody. 

Three-Dimensional Culture 

For 3D culture experiments, cells were grown in 24-well plates on 30% Matrigel (BD Bioscience) that was allowed to set for 15 minutes at 37°C in order to form a gel of 1-mm thickness. The bottom layer was then covered with 2 × 10^5 cells mixed 1:1 with 30% Matrigel in a total volume of 600 μl. Growth medium containing 2% Matrigel was replaced every 2 days, and the cells were left to grow for 12-14 days to allow development of extensive tubule network, after which treatment with inhibitor was applied for indicated incubation.
times. Photographs of the 3D cultures were taken using a Nikon Eclipse T-200 inverted phase-contrast microscope equipped with an Olympus digital camera. The nuclei were stained with Hoechst No. 33342; the cleaved caspase-3 was detected with cleaved caspase-3–specific antibody.

**Cell Viability Assays**

**SRB Assay.** For growth studies on colon cancer cell lines, the sulforhodamine B (SRB, SIGMA) assay was used. Firstly, tumor cells were seeded into 96-well microtiter plates and were allowed to attach overnight. Thereafter, the cell number in treated versus control wells was estimated after treatment with 10% trichloroacetic acid and staining with 0.4% SRB in 1% acetic acid. The percentage of viable cell was plotted each time. SD was used for error bar generation.

**MTS Viability/Cytotoxicity Assay.** Cell viability of NIH3T3, HepG2 cells, and WJ-MSCs was determined colorimetrically in a 96-well plate assay using the tetrazolium compound MTS, which is bioreduced by cells into a colored formazan product that is soluble in tissue culture medium [26]. This conversion is presumably accomplished by NADPH or NADH produced by dehydrogenase enzymes in metabolically active (viable) cells.

The MTS (CellTiter 96 AQueousOne, Promega, USA) assay was performed following the manufacturer's recommendations. Briefly, NIH3T3, HepG2 cells, and WJ-MSCs were plated into 96-well microtiter plates at a concentration of 2.5×10^3, 5×10^3 cells and NIH3T3, HEPG2 cells, and WJ-MSCs were plated into 96-well microtiter plates at a concentration of 2.5×10^3, 5×10^3 cells and performed following the manufacturer's recommendations. Briefly, enzymes in metabolically active (viable) cells.

**Phosphoprotein ELISA Measurements**

For phosphoproteomic analysis, cells were seeded on 96-well plates at 20,000 cells/well. The following day, increasing concentrations of DPS-2 (1 μM, 2 μM, 5 μM, and 10 μM) were added to the cells in triplicates for 24 hours. After incubation, the medium was removed and cells were lysed directly in the wells with Protavio lysis buffer mix. Triplicates of the cell lysates were pulled together and normalized according to total protein concentration of the samples. bead-based Luminex ELISA assays were used in a multiplex format to quantify the activity of phosphoproteins.

**In Vivo Studies**

The procedures in animals were performed in accordance with local animal ethics committees. A total of 2×10^6 Colo-205 cells diluted in PBS were injected subcutaneously in both left and right flanks of athymic mice. Tumors were allowed to grow for 8 days before inhibitor treatment was initiated. The mice were separated into three groups: untreated (four mice), DMSO treated (three mice), and inhibitor treated (five mice). The group of untreated mice was not given anything. DMSO mice were injected daily with 100 μl of 5% DMSO diluted in water. Inhibitor-treated mice were injected daily with 100 μl of the inhibitor in a final concentration of 0.6 μg/ml diluted in 5% DMSO. All injections of DMSO and inhibitor were performed intratumorally. Tumor sizes were measured with calipers every 3-4 days for a total period of 19 days after the injection of cancer cells. Tumor volume was calculated by the formula (V = length × width × depth), and comparative graphs were created. SD was used for error bar generation between all tumors of the same group of animals. Statistical analysis of the data was performed using two-way ANOVA, repeated measures test in Graphpad Prism 6.0. Mice were sacrificed only due to tumor burden.
Results

Chemistry

Synthesis of DPS-2. The key intermediate 6-methoxy-2-(4-methoxynaphthyl)-benzo[b]thiophene was prepared by the cyclization rearrangement produced by polyphosphoric acid (PPA) as described in the literature by Jones [27] and is depicted in Figure 2. The intermediate ether side chain methyl 4-(2-(piperidin-1-yl)ethoxy) benzoic acid hydrochloride was prepared by alkylation of methyl 4-hydroxybenzoate with 1-(2-chloroethyl) piperidine hydrochloride by

Figure 3. DPS-2 dramatically reduces cell viability of colon and melanoma cancer cell lines, while it affects cell viability of NIH3T3 and HepG2 cells in higher concentrations and shows very low toxicity in WJ-MSCs. (A) Cell Viability in RKO, HT29, and Colo-205 cell lines was measured using the SRB assay after 72-hour treatment with increasing concentrations of DPS-2 inhibitor. PLX4720 inhibitor was used as a positive control for cell viability reduction. (B) Light microscope images of 2D culture in RKO cell line after treatment with 2 μM, 5 μM, and 10 μM of DPS-2 inhibitor for 72 hours. (C) Cell Viability in Caco-2, HCT116, and DLD-1 cell lines was measured, using the SRB assay, after 72-hour treatment with increasing concentrations of DPS-2 inhibitor. Data are representative for two independent experiments, each of which was performed in duplicates. SD was used for error bar generation. (D) The effect of different concentrations (0-10 μM) of DPS-2 in five melanoma cell lines treated for 24 and 72 hours. All data are presented as the mean ± SD. (E) Percentage of cytotoxicity in WJ-MSCs cells after 48 hours of incubation with various concentrations of DPS-2 and respective survival curves (y = % viability, x = concentration μM). Cell viability was assessed using the MTS assay. Data are presented as mean of cell survival compared with negative control (cell survival assumed 100%). (F) Cell viability in NIH3T3 cell line was measured after 48-hour treatment with increasing concentrations of DPS-2 inhibitor. (G) Cell viability in HepG2 cell line was measured after 48-hour treatment with increasing concentrations of DPS-2 inhibitor. Cell viability was assessed using the MTS assay. Data are presented as mean of cell survival compared with negative control (cell survival assumed 100%). The 0.2% DMSO diluted in DMEM was used as a negative control for cell viability reduction. IC50 values are given for each graph. Experiments were performed in triplicates. SD was used for error bar generation.
means of powdered anhydrous potassium carbonate followed by base hydrolysis. Friedel-Crafts aroylation of 6-methoxy-2-2(4-methoxyphenyl)-benzo[\(\text{b}\)]thiophene with methyl 4-(2-(piperidin-1-yl)ethoxy)benzoic acid chloride and LAH reduction of the corresponding benzo[\(\text{b}\)]thien-3-yl ketone provided the desired DPS-2 (Figure 2).

**Effect of DPS-2 on cell viability of colon cancer and melanoma cell lines**

We initially examined the effect of DPS-2 on cell viability of colon cancer cell lines, bearing a different set of mutations, in order to have a primary assessment of the compound’s efficacy as an antiproliferative agent in colon tumors. Towards this direction, DPS-2 managed to reduce cell viability by more than 70% in all tested colon cancer cell lines, RKO, HT29, Colo-205, HCT116, and DLD-1, in concentration equal to or higher than 5 \(\mu\text{M}\) after 72-hour treatment (Figure 3, A and C). Caco-2, an intermediate adenoma cell line, was more resistant to the treatment with 5 \(\mu\text{M}\) of DPS-2, with an average reduction of 40% in cell viability (Figure 3C). All tested cell lines showed resistance to the action of the compound when treated with concentrations lower than 2 \(\mu\text{M}\) for 72 hours (Figure 3, A-C). PLX4720, a BRAFV600E selective inhibitor, was used a control for the reduction of cell viability in RKO, HT29, and Colo-205 cell lines, bearing the BRAFV600E mutation.

We then investigated the effect of DPS-2 on cell viability in five different melanoma cell lines (Figure 3D). All the cells had decreased survival rates;
however, there was a difference in sensitivity to DPS-2 induced effects. The more sensitive V600E BRAF mutated cell lines SK-MEL19 and WM3248 exhibited the greatest overall decrease in viability with IC50 < 5 μM, whereas the more resistant cell lines (WM35 and A375) had less of a response to increasing concentrations of DPS-2. Moreover, the NRAS Q61K mutated WM3060 cell line showed significant sensitivity to DPS-2 with IC50 < 5 μM (Figure 3D). The five cell lines with different mutations and survival rates were further used for phosphoprotein measurements presented in Figure 4C. Since DPS-2 presents a dramatic effect on cell viability of tumor cells, the potential cell toxicity was tested in appropriate models. Thus, the in vitro response of WJ-MSCs to eight concentrations of DPS-2 and of NIH3T3 and HepG2 cells to seven concentrations of DPS-2 was tested. The two latter cell lines share similar characteristics with those proposed by the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) for toxicity studies [28]. Human umbilical cord stem cells, WJ-MSCs, retained their viability even when they were treated with the highest concentrations of the compounds (Figure 3, E-G). NIH3T3 and HepG2 were also resistant, with IC50 values of 18.75 μM and 18.67 μM, respectively. This indicates a selective effect of this agent towards tumor cell lines while leaving unaffected normal cells.
Figure 4. DPS-2 induces apoptosis and reduces autophagy in cancer cell lines. (A, B) Cell viability in RKO, HT29, Colo-205, Caco-2, HCT116, and DLD-1 cell lines were measured, using the SRB assay, after 24-hour treatment with increasing concentrations of DPS-2 inhibitor. Data are representative for two independent experiments, each of which was performed in duplicates. SD was used for error bar generation. (C, left panel) Light and confocal microscope images of 2D culture in RKO cell line after treatment with 2 μM and 5 μM of DPS-2 for 24 hours. For apoptotic marker staining, cells were incubated and stained with Hoechst (first line) and with cleaved Caspase 3 antibody (second line) and merged (third column) in order to detect the presence of apoptotic cell death due to treatment (second, third row), as compared to untreated control (first row). Cells were also visualized under light microscope (fourth row). PLX4720 was used as a negative control for apoptosis. (Right panel) Western blot analysis of protein levels of the apoptotic markers PARP-1 and Caspase-3 after 24-hour treatment with 2 μM and 5 μM of DPS-2 in RKO, HT29, and Colo-205 cell lines. Protein levels were normalized against tubulin. TRAIL was used as a positive control for the presence of apoptotic cell death. PLX4720 was used as a negative control for apoptosis. Data are representative for three independent experiments. (D) Western blot analysis of protein levels of the apoptotic markers PARP-1 and Caspase-3 after 48-hour treatment with 2 μM and of DPS-2 in RKO, HT29, and Colo-205 cell lines. Protein levels were normalized against tubulin. (E) Light and confocal microscope images of 2D culture in HT29 and Colo-205 cell lines after treatment with 2 μM and 5 μM of DPS-2 for 48 hours. For apoptotic marker staining, cells were incubated and stained with Hoechst (first line) and with cleaved Caspase 3 antibody (second line) and merged (third line) in order to detect the presence of apoptotic cell death due to treatment (second, third row), as compared to untreated control (first row). Cells were also visualized under light microscope (fourth column). PLX4720 was used as a negative control for apoptosis. (F) Western blot analysis of protein levels of the necroptotic markers RIP-1 (RIP) and RIP-3 (RIPK3) and the autophagic marker p62 after 24 hours (left panel) and 48 hours (right panel) of treatment with 2 μM and 5 μM of DPS-2 in RKO, HT29, and Colo-205 cell lines. Protein levels were normalized against actin.
Figure 4. (continued.)
Effects of DPS-2 on apoptosis and autophagy in colon cancer cell lines

Since DPS-2 efficiently reduces cell viability in colon cancer cell lines after 72 hours of treatment, we then searched into its antiproliferative mechanism of action. First, we examined the effect of DPS-2 on cell viability after treatment for a shorter time period. Treatment with increasing concentrations of DPS-2 for 24 hours revealed a more modest efficiency of the compound in reducing cell viability of the examined cell lines RKO, HT29, Colo-205, Caco-2, and HCT116 as compared to its efficiency of the compound in reducing cell viability of the examined cell lines after 72-hour treatment. Except for RKO, cell viability in HT29, Colo-205, and HCT116 was reduced in DPS-2 concentrations equal to or higher than 10 μM (Figure 4, A and B). Caco-2 cell line was again more resistant, with its viability significantly reduced only after treatment with 20 μM of the compound (Figure 4B).

In order to examine thoroughly the cell viability effect of DPS-2 on colon cancer cell lines, analysis of apoptosis, as well as potential induction of either autophagy and/or necroptosis after cell treatments with DPS-2, was performed. Apoptotic marker staining of RKO cell line after 24-hour treatment with 2 μM or 5 μM DPS-2 revealed the presence of cleaved caspase-3 stained nuclei in both concentration treatments, as seen under confocal microscope (Figure 4C, left panel), revealing a putative induction of apoptosis by DPS-2, reflecting the reduction of cell viability even from the first 24 hours of treatment, observed in this cell line. The induction of apoptosis after these DPS-2 concentration treatments for 24 hours in RKO cells was also confirmed by the presence of Caspase-3 cleavage in Western blotting (Figure 4C, left panel). TRAIL treatment was used as a control for the induction of apoptosis in Western blots.

On the other hand, HT29 and Colo-205 cells did not show any evidence of apoptotic cell death either by cleaved Caspase-3 staining (data not shown) or by Caspase-3 cleavage detection using the Western blot assay after 24-hour treatment with 2 μM or 5 μM DPS-2 (Figure 4C, right panel). Interestingly, both cell lines HT29 and Colo-205 became sensitive to apoptotic cell death after a longer period of 48-hour treatment with DPS-2, as shown by Caspase-3 cleavage. In detail, 5 μM of DPS-2 caused Caspase-3 cleavage in HT29 cells, as shown both by staining with cleaved Caspase-3 antibody under confocal microscope and by the 19-kDa cleaved Caspase-3 detection in Western blot. Two micromolar DPS-2 also resulted in cleaved Caspase-3 staining (Figure 4, D and E HT29). Treatment of Colo-205 with both 2 μM and 5 μM DPS-2 resulted in the 19-kDa cleaved Caspase-3 detection in Western blot, although the control sample of untreated cells also presented the same 19-kDa band of cleaved Caspase-3 (Figure 4D). However, staining with antibody for cleaved Caspase-3 under confocal microscope revealed a highly stained cell population after treatment with 5 μM DPS-2 (Figure 4E Colo-205).

Interestingly, autophagy-related p62 protein levels were induced in all cell lines RKO, HT29, and Colo-205 after treatment for both 24 hours and 48 hours with both 2 μM and 5 μM DPS-2 concentrations (Figure 4F), indicating a potent effect of DPS-2 on autophagy blockade.

Thus, the potent anticancer effect of DPS-2 can be the result of the activation of the apoptotic machinery in addition to the inhibition of autophagy, a tumor survival mechanism.

In turn, the potential effect of DPS-2 treatments on necroptosis was examined. Treatment of colon cancer cell lines RKO and HT29 with 2 μM and 5 μM of DPS-2 for 24 and 48 hours revealed a slight overexpression of RIP1 upon the longer time treatment. The same result was achieved in Colo-205 cells only after treatment with 5 μM DPS-2 (Figure 4F). Moreover, RIPK3 isoform 1 (55 kDa) protein levels were in average not affected by the treatments, except for RKO, where an induction of this isoform 1 levels was recorded. On the other hand, RIPK3 isoform 2 (30 kDa) expression was strongly suppressed in HT29 cell line after treatment with both 2 μM and 5 μM DPS-2 after 24 and 48 hours, while the mildest reduction in these protein levels was observed in Colo-205 cells only after 48 hours of treatment. In RKO cells RIPK3 isoform 2, protein levels remained almost the same (Figure 4F).

Induction of apoptosis by DPS-2 in 3D colon cancer cultures

To test treatment conditions that mimic the real tumor microenvironment, Colo-205, one of the most sensitive to DPS-2 cell line, was grown in 3D cultures and formed tumors in Matrigel. Treatment with 2 μM or 5 μM DPS-2 was initiated after completion of tumor formation and lasted for 48 hours (Figure 5A) and 72 hours (Figure 5B). Though the tumor mass was not affected significantly due to the treatments, cell staining with Hoechst and cleaved
Figure 5. DPS-2 induces apoptosis of colon cancer cells in 3D cultures. Light and confocal microscope images of three-dimensional culture in Colo-205 cell line after treatment with 2 μM (second row) or 5 μM (third row) of DPS-2 for 48 hours (A) and 72 hours (B), as compared to control untreated tumors (first row). Tumor treatments started after 12e-day tumor formation. For apoptotic marker staining under confocal microscopy, Colo-205 tumors were incubated and stained with Hoechst (first column) and with cleaved Caspase 3 antibody (second column) and merged (third column) in order to detect the presence of apoptotic cell death, as compared to untreated control (first row). Tumors were also visualized under light microscope and their mass was measured (fourth column).
Caspase-3 under confocal microscopy revealed the presence of apoptotic cells within the tumors under all of the above treatments (Figure 5, A and B) Thus, it is obvious that the apoptotic effect of DPS-2 is also present in colon cancer tumors formed in 3D Matrigel.

**DPS-2 Acts as a Dual Inhibitor of MEK/ERK and PI3K/Akt Pathways**

In order to determine molecular targets associated with colon cancer, which could be potent targets of DPS-2, we next examined the effect of DPS-2 treatments on molecular components of the different MAPK signaling pathways. Thus, we examined the effect of 2 μM and 5 μM DPS-2 treatments on BRAF/MEK/ERK, PI3K/Akt/mTOR, p-p38/MAPK, and JNK/MAPK pathways. Treatments took place for 1 hour and 24 hours in order to assess the effect of the compound in both early and later time points. As a result, a potent inhibition of pERK1/2 was observed in Colo-205, which increased in higher concentration and longer time treatment, as shown by Western blot. PLX4720, a BRAFV600E selective inhibitor, was used as control for pMEK and pERK inhibition. In detail, pERK protein levels were reduced by 20% and 30% after treatment with 2 μM DPS-2 for 1 hour and 24 hours, respectively. The inhibition of ERK kinase phosphorylation was further increased, resulting in a 40% to
50% reduction on pERK levels after treatment with 5 μM DPS-2 for 1 hour and 24 hours, respectively (Figure 6A). In RKO cell line, pERK protein levels were reduced by 20% only after 1 hour early time treatment with 5 μM DPS-2. Interestingly, in HT29 cells, pERK levels were increased after treatments with the compound. pMEK protein levels were not significantly affected by DPS-2 treatments. These results strongly indicate a role for DPS-2 as a potent MEK pathway inhibitor, though in selected colon cancer cell lines.

Except for its action in the BRAF/MEK/ERK pathway, DPS-2 reduced pAkt 473 protein levels in RKO, HT29, and Colo-205 after 1-hour treatment in both concentrations 2 μM and 5 μM by 20%, 30% and 50%, respectively. The inhibitory effect was sustained after 24-hour treatments in RKO and HT29 but not in Colo-205 cells (Figure 6B). In RKO cells, DPS-2 reduced also pAkt 308 levels by 20%. In the same cell line, pS6R protein levels were reduced after both 1- and 24-hour treatment, with the inhibition reaching a level of 40% after 24-hour treatment with 5 μM DPS-2. Similarly, in the case of Colo-205, pS6R was suppressed after 1 hour of treatment with the highest concentration of DPS-2. In longer time treatments with the same concentration of the compound, as in 24 hours, pS6R levels are restored. In HT29 cells, there was no reduction in pS6R levels observed (Figure 6B). According to these data, DPS-2 can act as a potent inhibitor of Akt phosphorylation at position 473 and less at position 308. It may also modulate mTOR pathway in specific colon cancer cell lines.

Finally, treatment of RKO cells with 2 μM or 5 μM DPS-2 for both 1 hour and 24 hours resulted in an induction of pJNK, while the same was true for HT29 and Colo-205 only within the first hour of treatment. Furthermore, in Colo-205 cell line, the same concentration treatments resulted also in p-p38 induction after early time point treatments (data not shown). These findings indicate a possible role of the p-p38/ MAPK and JNK/MAPK pathways upon DPS-2 treatments, under some conditions in selected colon cancer cell lines.

In parallel analysis, the phosphoproteomic response to DPS-2 in melanoma cell lines was evaluated by measuring the activity of three major phosphoproteins (MEK1, ERK1, AKT1) involved in regulating melanoma growth and survival (Figure 6C). Activity of all three phosphoproteins was found significantly decreased in responsive cell lines (WM3248, SK-MEL19, and WM3060), with most responsive SK-MEL19 showing complete inhibition of MEK/ERK signaling in low micromolar concentrations. Interestingly, phosphorylation of MEK showed a vast decrease, especially in SK-MEL19 and WM3060, in contrast to CRC cell lines, where pMEK levels in Western blot analysis remained unaffected after treatment with the compound. DPS-2 administration also caused a decrease in phosphorylation of AKT in all five melanoma cell lines.

All the above data could indicate that the potent anticancer effect of DPS-2 can be associated to the dual inhibition of two key proliferative/survival pathways, like the MEK/ERK and PI3K/ Akt.

Inhibitory effects of DPS-2 on the development of colon tumors in vivo

Taking under consideration the antiproliferative, autophagy, and MEK/Akt kinase-suppressive roles of DPS-2 against colon cancer cell lines, our final goal was to examine whether DPS-2 could be also effective against colon tumors in vivo. Thus, nude mice were injected subcutaneously in both left and right flanks with Colo-205 colon cancer cells, and after tumor formation, mice were injected daily with 0.6 μg/μl diluted in 5% DMSO for a time period of 9 days after the initiation of the treatment. As shown in Figure 7, treatment with DPS-2 caused a reduction on tumor growth rate, resulting in tumor sizes of treated mice reduced by around seven times compared to untreated mice by the end of the injections. Statistical analysis of the results is presented in Tables 1 and 2. Thus, DPS-2 is very potent in vivo against mouse xenografts of colorectal tumor cells.
Synthetic Approaches

Benzo[b]thiophene scaffold is one of the privileged structures in drug discovery as this core exhibits various biological activities allowing them to act as antimicrobial, anticancer, anti-inflammatory, antioxidant, antitubercular, antiadipic, or anticonvulsant agents and many more. Further, numerous benzo[b]thiophene-based compounds as clinical drugs have been extensively used to treat various types of diseases with high therapeutic potency, which has led to their extensive developments [29].

Benzo[b]thiophene derivatives attracted considerable attention for medicinal chemists towards development of anticancer drugs, and several attempts were made for modifying the benzo[b]thiophene nucleus to improve their antitumor activities. Modifications on the benzo[b]thiophene nucleus have resulted in the synthesis of two anticancer drugs, namely, arzoxifene and raloxifene. Arzoxifene is a highly effective agent for prevention of mammary cancer induced in the rat by the carcinogen nitrosomethylurea and is significantly more potent than raloxifene in this regard [30]. Raloxifene is used in the prevention of osteoporosis in postmenopausal women and to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer [31]. Additionally, benzo[b]thiophen-3-yl)-2,2,2-trifluoroethanol interacts with the BPII pocket of BRAF, resulting in potent BRAF kinase inhibition [32].

![Figure 7](image_url)

**Figure 7.** DPS-2 blocks the development of Colo-205 tumors in nude mice. Inhibition of Colo-205 tumor development in nude mice after treatment with DPS-2. The mice were separated into three groups: untreated (mice ctr), DMSO treated (mice DMSO), and inhibitor treated (mice DMSO+drug). Chart lines represent tumor growth within a total period of 19 days after the injection of cancer cells. SD was used for error bar generation between all tumors of the same group of animals.

### Discussion

**Synthetic Approaches**

Benzo[b]thiophene scaffold is one of the privileged structures in drug discovery as this core exhibits various biological activities allowing them to act as antimicrobial, anticancer, anti-inflammatory, antioxidant, antitubercular, antiadipic, or anticonvulsant agents and many more. Further, numerous benzo[b]thiophene-based compounds as clinical drugs have been extensively used to treat various types of diseases with high therapeutic potency, which has led to their extensive developments [29].

Benzo[b]thiophene derivatives attracted considerable attention for medicinal chemists towards development of anticancer drugs, and several attempts were made for modifying the benzo[b]thiophene nucleus to improve their antitumor activities. Modifications on the benzo[b]thiophene nucleus have resulted in the synthesis of two anticancer drugs, namely, arzoxifene and raloxifene. Arzoxifene is a highly effective agent for prevention of mammary cancer induced in the rat by the carcinogen nitrosomethylurea and is significantly more potent than raloxifene in this regard [30]. Raloxifene is used in the prevention of osteoporosis in postmenopausal women and to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer [31]. Additionally, benzo[b]thiophen-3-yl)-2,2,2-trifluoroethanol interacts with the BPII pocket of BRAF, resulting in potent BRAF kinase inhibition [32].

### Table 1. Statistical Analysis of the In Vivo Results According to Time Per Treatment Group

| Time | Treatment Group | Day 8   | Day 12  | Day 15  | Day 19  |
|------|-----------------|---------|---------|---------|---------|
|      | Control         | ns      | ns      | ns      | ns      |
| Day 8| DMSO            | ns      | ns      | ns      | ns      |
|      | DPS-2           | ns      | ns      | ns      | ns      |
| Day 12| Control       | ns      | ns      | ns      | ns      |
|      | DMSO            | ns      | ns      | ns      | ns      |
|      | DPS-2           | ns      | ns      | ns      | ns      |
| Day 15| Control     | ***     | **      | ns      | ns      |
|      | DMSO            | ns      | ns      | ns      | ns      |
|      | DPS-2           | ns      | ns      | ns      | ns      |
| Day 19| Control     | ***     | ***     | ***     | ns      |
|      | DMSO            | ***     | ***     | ***     | ns      |
|      | DPS-2           | ns      | ns      | ns      | ns      |

Analysis was performed using two-way ANOVA, repeated measures test.

*ns: p > .05, * p < .05, ** p < .01, *** p < .001.

### Table 2. Statistical Analysis of the In Vivo Results According to Treatment Group Per Time

| Treatment Group | Time   | Control | DMSO | DPS-2 |
|-----------------|--------|---------|------|-------|
|                 | Day 8  | ns      | ns   | ns    |
| Day 12          | ns     | ns      | ns   | ns    |
| Day 15          | ns     | ns      | ns   | ns    |

Analysis was performed using two-way ANOVA, repeated measures test.

*ns: p > .05, * p < .05, ** p < .01, *** p < .001.
Encouraged by the above biological testing results, we proceeded to evaluate DPS-2 against CRC and melanoma tumor cells in vivo as well as colon tumors in vivo.

**Necessity for treatment of KRAS- BRAF mutant CRC and RAS mutant melanoma. A new potent anticancer agent with apoptotic and autophagy-suppressing properties against CRC**

Despite the recent development of efficient targeted therapies in oncology, so far, no specific cancer therapy against CRC tumors bearing KRAS or BRAF mutations has reached the clinic. Although there are already specific BRAF kinase inhibitors-targeted drugs in the metastatic BRAFV600E mutant melanoma with FDA approval (vemurafenib 2011, dabrafenib 2013), these inhibitors have not yielded positive results in clinical studies for patients with BRAF mutant colorectal cancer. Moreover, the inhibitors against BRAFV600E melanoma have opposite effects on tumors with normal BRAF and/or mutated RAS [33,34]. Novel drugs targeting either the KRAS/BRAF oncoproteins or their downstream components which mediate their oncogenic activities are currently being developed with the aim to revert KRAS/BRAF dependent tumor properties. Towards this direction, monotherapies of novel MEK inhibitors and their combinatorial treatments are in progress in different tumor types (reviewed by [35]). In the current study, synthesis and biological evaluation of a potent new anticancer agent DPS-2 against CRC and melanoma tumor cells are presented. DPS-2 can cause tumor cell apoptosis in 2D and 3D cultures, as well as in mouse xenografts. In tumors, autophagy can promote cancer cell survival and provide cancer cells with a highly plastic and dynamic mechanism to escape tumor therapies [36]. It is of interest that the potent anticancer effect of DPS-2 can be the result of the activation of the apoptotic machinery in addition to the inhibition of autophagy, a tumor survival mechanism. On the other hand, the activity of DPS-2 does not appear to be mediated by necroptotic mechanisms in most treatment protocols presented here.

**Combinatorial and Dual BRAF/MEK/PI3K Inhibition for Cancer Therapy**

Rational approaches for combination therapy strategies targeting the MAP kinase pathway are described in a recent review [37]. Resistance mechanisms to targeted therapeutic agents against BRAF/MEK by reverse-translational approaches have recently facilitated the establishment of novel efficient combinatorial treatments of BRAF and MEK inhibitors against mutBRAF tumors, either in metastatic melanoma [38] or in non–small cell lung cancer [39]. As an alternative approach, RO5126766 is a first-in-class selective dual BRAF/CRAF and MEK inhibitor currently in early development for advanced solid tumors [40]. In the present study, evidence is presented that DPS-2 is a novel dual MEK/ERK and PI3K/ AKT cell signaling pathway inhibitor in melanoma and colorectal cancer cells. Since these two pathways are key pathways for the proliferation and survival of tumor cells, the potent anticancer activity of the new inhibitor DPS-2 can be mediated at least partially through this dual inhibition.

It has been shown in several studies that PI3K pathway activation mediates resistance to MEK inhibitors [41]. Tumors with both KRAS and phosphoinositide 3-kinase mutations are unlikely to respond to the inhibition of the MEK pathway alone or the PI3K pathway alone but will require effective inhibition of both MEK and PI3K/AKT pathway signaling. Preclinical data suggest that BRAF/MEK and PI3K/mTOR inhibition may delay tumor growth but may not affect tumor size regression and is likely to be inferior to MEK and PI3K inhibition. The combination of specific PI3K inhibitors, rather than dual mTOR/PI3K inhibitors, with MEK inhibitors may result in greater synergy [42]. Clinical trials on dual targeted inhibition with MEK revealed that CRC patients harboring mutations in both pathways had tumor regression ranging between 2% and 64% when treated with PI3K and MAPK inhibitors. Dual pathway inhibition may potentially exhibit greater efficacy than single targeted therapy at the expense of greater toxicity [43].

In the present study, the potent anticancer effect of the new compound DPS-2 in 2D and 3D tumor cell cultures and in mouse xenografts is associated with efficient inhibition of MER/ERK and PI3K/AKT pathways known to be involved in colon cancer and melanoma progression. It is expected that DPS-2 potent activity can lead to further exploitation into new potential efficient anticancer treatments either alone or in combination, once further validated at the preclinical level and finally in the clinic.

**Benefits of One Small Molecule Instead of Two or More for Blocking Two Pathways**

Drug toxicity and low organism tolerability are two of the main drawbacks in drug-mediated cancer treatment. Thus, combinatorial treatments of solid tumors with small molecule inhibitors that target more than one crucial pathway, though effective, can lead to severe adverse effects [44,45]. On the other hand, the use of multitarget small molecule inhibitors, although appealing for bypassing acquired resistance of specific tumors to drug treatment, has shown dismal performances in clinical trials since these inhibitors usually demonstrate off-target toxicity due to their disability to distinguish between cancer and normal cells [46]. A solution to this problem would be the development of small molecule inhibitors with a narrower field of action and higher specificity. These could act on key kinases of the same [40,47] or cross-talking [48] pathways.

In the present study, we showed that DPS-2 is a single agent that acts as a dual MEK/ERK and PI3K/AKT pathway inhibitor, showing high efficiency in blocking ERK and AKT phosphorylation, respectively, in selected colon cancer and melanoma cell lines, as shown by decreased pERK and pS6R levels in Western blot analysis. Nevertheless, it is shown here that DPS-2 may have differential effects not only on CRC and melanoma cells but even on different cell lines of the same cancer type, an observation that has already been presented for other known inhibitors [49]. Interestingly, HT29 cell line was found resistant to DPS-2 action regarding both BRAF/MEK and PI3K/AKT/mTOR pathways, with pERK and pS6R protein levels becoming elevated upon DPS-2 treatment. Induction of phosphorylation of these proteins could be due to several factors. As a speculation, HT-29 express high levels of EGFR [50], which have been indicated as a causal factor for the observed intrinsic resistance of colorectal cancer cell lines to BRAFV600E inhibitor treatment [12]. The presence of P449T heterozygous mutation in PI3KCA in HT29 could also play a role for the observed resistance. Colo-205, the most sensitive cell line to DPS-2 treatment, is PI3KCA wild-type. We have previously correlated activity of BRAF/MEK/ERK pathway with the autophagy state in CRC lines [49]. According to this, HT29 shows intrinsic increased levels of autophagic markers, a fact which could contribute to the induction of ERK phosphorylation upon DPS-2 treatment. Finally, an interaction between ERK and S6R proteins has been established previously [51], which could somehow portray the concomitant increase in both markers. Definitely, a more detailed
The Need for In Vitro Toxicity Screening of Candidate Therapeutic Molecules

Preclinical toxicity screening is a crucial test for the assessment of any novel candidate drug before its potent further evaluation in clinical trials. Given that laboratory animal testing requires millions of small animal sacrifices for the in vitro evaluation of thousands of chemicals yearly, thus creating a huge ethical, economic, and ecologic burden to the societies worldwide, in vitro drug screening has arisen as an economically and ecologically advantageous alternative to predict human toxicity in reliable and easier manner.

Based on the above, apart from its efficiency on suppressing the viability of colon cancer and melanoma cell lines, the cytotoxic effect of DPS-2 on other mammalian cell lines was also assessed. More specifically, we used two validated cell models, globally used for the assessment of in vitro cytotoxicity: NIH3T3, an immortalized murine embryonic fibroblast cell line, and HepG2, a human hepatocellular carcinoma cell line [52]. Specifically, NIH 3T3 cells are very similar to BALB/c 3T3 cells, which are proposed by ICCVAM as standard models for the prediction of acute in vitro cytotoxicity [28]. In addition, we examined the cytotoxic effect of DPS-2 on a mesenchymal stem cell line isolated from human umbilical cord, WJ-MSCs, in order to also assess its effect on nontransformed cells.

Notably, the antiproliferative effect of DPS-2 was mitigated in HepG2 and NIH3T3, with only concentrations higher than 12.5 μM being able to cause a reduction in the viability of these cells. More interestingly, treatment with DPS-2 had no significant suppressive effect on cell viability of WJ-MSC even in high concentrations (up to 100 μM) of the agent.

Taken together, the above results clearly suggest that DPS-2 is a potent anticancer agent against colon cancer and melanoma cells while at the same time being nontoxic for normal cells.

Author contributions
L. A., V. Z., A. P., and D. P. designed the study. M. G., N. A., J. R., E. T., and I. C. performed experiments. V. Z., A. P., and D. P. wrote and edited the paper with input from the other authors.

Acknowledgements and Funding
This work was supported by Greece and the European Regional Development Fund of the European Union under the O.P. Competitiveness, Entrepreneurship and Innovation NSRF 2007-2013 and the Regional Operational Program of Attica (STHENOS project MIS 447985 within GSRT’S KRIPIPS) and the grant EU Horizon 2020-MelPlex (grant no. 642295). The salary of the Phd candidate M. G. was financed by Greece and the EU (European Regional Development Fund).

Conflicts of Interest
The authors declare no conflict of interest.

References
[1] Colussi D, Brandi G, Bazzoli F, and Ricciardiello L (2013). Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int J Mol Sci 14, 16365–16385. http://dx.doi.org/10.3390/ijms140816365.
[2] Walther A, Johnston E, Swanton C, Midgley R, Tomlinson I, and Kerr D (2009). Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9, 489–499. http://dx.doi.org/10.1038/nrc2645.
[3] Thorstensen L, Lind GE, Lovig T, Diep CB, Mæling GJ, Rognum TOLothe RA (2005). Genetic and epigenetic changes of components affecting the WNT pathway in colorectal carcinomas stratified by microsatellite instability. Neoplasia 7, 99–108. http://dx.doi.org/10.1593/neo.040448.
[4] Tripathi S, Bellaccimia L, Cheung MS, and Bose RN (2016). Correlation between gene variants, signaling pathways, and efficacy of chemotherapy drugs against colon cancers. Cancer Inform 15, 1–13. http://dx.doi.org/10.4137/CIN.2016.00506.
[5] Montagut C and Sentenjam J (2009). Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett 285, 123–134. http://dx.doi.org/10.1016/j.clet.2009.01.022.
[6] Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Arai S, Wada H, and Fujimoto J, et al (1999). Constitutive activation of the 11–143 kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18, 813–822. http://dx.doi.org/10.1038/sj.onc.1202567.
[7] Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Wolfenden H, Garrett MJ, and Bottomley W, et al (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949–954. http://dx.doi.org/10.1038/nature00766.
[8] Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, and Haass NK, et al (2008). Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimalanoma activity. Proc Natl Acad Sci U S A 105, 3041–3046. http://dx.doi.org/10.1073/pnas.0717411105.
[9] Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, and Habers G, et al (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596–599. http://dx.doi.org/10.1038/nature09454.
[10] Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, and Maor M, et al (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364, 2507–2516. http://dx.doi.org/10.1056/NEJMoa1103782.
[11] Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, Schostack K, Simcos ME, Kopetz S, and Heimbrook D, et al (2012). Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-Mutation colorectal cancer. Cancer Res 72, 779–789. http://dx.doi.org/10.1158/0008-5472.CAN-11-2941.
[12] Pralahad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, and Bernards R (2012). Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100–103. http://dx.doi.org/10.1038/nature10868.
[13] Kopetz S, Desai J, Chan E, Hecht JR, O’Dwyer PJ, Lee RJ, Nolop B, and Saltz L (2010). PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol 28, 3534. http://dx.doi.org/10.1200/JCO.2010.28.15_suppl.3534.
[14] Tabernero J, Chan E, Baselga J, Blay JY, Chau I, Hyman DM, Raje NS, Wolf J, Arii S, Wada H, and Fujimoto J, et al (1999). Constitutive activation of the 41–43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18, 813–822. http://dx.doi.org/10.1038/sj.onc.1202567.
[15] Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, Schostack K, Simcos ME, Kopetz S, and Heimbrook D, et al (2012). Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-Mutation colorectal cancer. Cancer Res 72, 779–789. http://dx.doi.org/10.1158/0008-5472.CAN-11-2941.
[16] Do K, Speranza G, Bishop R, Khin S, Rubinstein L, Kinders RJ, Datialis M, Eugeni M, Lam MH, and Doyle LA, et al (2015). Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer. Invest New Drugs 33, 720–728. http://dx.doi.org/10.1007/s10637-015-0212-z.
[17] Zimmer L, Barlesi F, Martinez-Garcia M, Diers V, Schellens JH, Spano JP, Middleton MR, Calvo E, Paz-Ares L, and Larkin J, et al (2014). Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655).
in selected patients with advanced cancer with RAS-RAF mutations. Clin Cancer Res 20, 4251–4261. http://dx.doi.org/10.1158/1078-0432.CCR-14-0341.

Hatzivassiliou G, Liu B, O’Brien C, Sporer JM, Hoeflck RP, Haverty PM, Soriano R, Forrest WF, Heldens S, and Chen H, et al (2012). ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol Cancer Ther 11, 1143–1154. http://dx.doi.org/10.1158/1535-7163.MCT-11-1010.

Corcoran RB, Araya CE, Falkhoos GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Mesersmith WA, Daud A, and Kurzrock R, et al (2015). Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J Clin Oncol 33, 4023–4031. http://dx.doi.org/10.1200/JCO.2015.63.2471.

Halowiec E, She QB, Ye Q, Pagliarini R, Sellers WR, Sotol DB, and Rosen N (2010). PI3KCA mutation uncouples tumor growth andcyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res 70, 6804–6814. http://dx.doi.org/10.1158/0008-5472.CAN-10-0409.

Cohen MH, Gootenberg J, Keegan P, and Pardoe R (2007). FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncology 12, 356–361. http://dx.doi.org/10.1634/theoncologist.12-3-356.

Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, and Groshley A, et al (2015). Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal cancer that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 16, 499–508. http://dx.doi.org/10.1016/S1470-2045(15)70127-0.

Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, A, Davies L, Pons JF, Whittaker S, Marais R, and Springer CJ (2013). Potent 28(3)-hydroxyphenyl)benzo[b]thien-3-yl[4-[2-(1-piperidinyl)ethoxy]-phenyl]methane derivatives leading to 6-hydroxy-2-(4-(2phenylthiophen-2-yl)phenyl)benzo[b]thiophene derivatives. J Med Chem 56, 4261–4272. http://dx.doi.org/10.1021/jm301093b.

Dumollard JY, Siena S, Cassidy J, Tabernero J, Burke S, Barugel M, Humblet Y, Bodoky G, Cunningham D, and Jassem J, et al (2010). Randomized, phase III trial of panitumumab versus infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFIRI4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28, 4697–4705. http://dx.doi.org/10.1200/JCO.2009.27.4860.

Christodoulou I, Kolisis FN, Papaevangelou D, and Zoumpourlis V (2013). Comparative evaluation of human mesenchymal stem cells of fetal (Wharton’s jelly) and adult (adipose tissue) origin during prolonged in vitro expansion: considerations for cytotherapy. Stem Cells Int 2013:46134. http://dx.doi.org/10.1155/2013/46134.

Malich G, Markovic B, and Winder C (1997). The sensitivity and specificity of Keri RS, Chand K, Budagumpi S, Balappa Somappa S, Patil SA, and Nagaraja and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J Clin Oncol 33, 4023–4031. http://dx.doi.org/10.1200/JCO.2015.63.2471.

Tabernero J, Van Geel R, Guren TK, Yaeger RD, Spreafico A, Faris JE, Yoshino T, A, McArthur, Dreno B, Atkinson V, Liszkay G, Di Giacomo AM, Mandala M, Demidov L, Stroyakovskiy D, and Thomas L, et al (2016). Cobimetinib combined with vemurafenib in advanced BRAF(V600E)-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol 17, 1248–1260. http://dx.doi.org/10.1016/S1470-2045(17)30679-4.

Martinez-Garcia M, Banerji U, Allandt J, Bahleda R, Dolly S, Krabe-Bodere F, Rojo F, Rouzier R, Guerin E, and Xu ZX, et al (2012). First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of R21256766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin Cancer Res 18, 4806–4819. http://dx.doi.org/10.1158/1078-0432.CCR-12-0742.

Wen C, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Lenger M, and Stegmeier F (2009). PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 69, 4286–4293. http://dx.doi.org/10.1158/0008-5472.CAN-08-4765.

Temraz S, Mukherji D, and Shamseddine A (2015). Dual inhibition of MEK and PI3K pathway in KRAS and BRAF mutated colorectal cancers. Int J Mol Sci 16, 22976–22988. http://dx.doi.org/10.3390/ijms16092276.

Shimizu T, Tolcher AW, Papadopoulos KP, Beerman M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays T, and Kaiser B, et al (2012). The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 18, 2316–2323. http://dx.doi.org/10.1158/1078-0432.CCR-11-2381.

Algazi AP, Posch C, Ortiz-Urda S, Cockrier A, Munster PN, and Daud A (2014). A phase 1 trial of BKM120 combined with vemurafenib in BRAF(V600E)/K mutant advanced melanoma. J Clin Oncol . http://dx.doi.org/10.1200/JCO.2014.32.15_suppl.9101.

Tabernero J, Van Geel R, Gunen TK, Vaeger RD, Spreafico A, F, Rouzier R, Guerin E, and Xu ZX, et al (2016). Phase 2 results: encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC). J Clin Oncol 34, http://dx.doi.org/10.1200.JCO.2016.34.15_suppl.3544.

Cheng H and Force T (2010). Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Prog Cardiovasc Dis 53, 114–120. http://dx.doi.org/10.1016/j.pcad.2010.06.006.

Liu TJ, Koul D, LaForte T, Tao N, Shem RJ, Mair SA, Garcia-Echeverria C, and Yang WK (2009). NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 8, 2204–2210. http://dx.doi.org/10.1158/1535-7163.MCT-09-0160.

Yu P, Ye L, Wang H, Gu G, Zhang J, Zhong J, and Tian J (2015). NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways. Tumour Biol 36, 2143–2153. http://dx.doi.org/10.1007/s13277-014-2824-x.
Goulielmaki M, Koutras E, Moysidou E, Vlasi M, Sasazuki T, Shirasawa S, Zografos G, Oikonomou E, and Pintzas A (2016). BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells. *Oncotarget* 7, 9188–9221. [http://dx.doi.org/10.18632/oncotarget.6942](http://dx.doi.org/10.18632/oncotarget.6942).

Solmi R, Lauriola M, Francesconi M, Martini D, Voltattorni M, Ceccarelli C, Ugolini G, Rosati G, Zanotti S, and Montroni I, et al (2008). Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines. *BMC Cancer* 8, http://dx.doi.org/10.1186/1471-2407-8-227.

Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, Taunton J, Sonenberg N, and Blenis J (2007). RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. *J Biol Chem* 282, 14056–14064. [http://dx.doi.org/10.1074/jbc.M700906200](http://dx.doi.org/10.1074/jbc.M700906200).

Shukla SJ, Huang R, Austin CP, and Xia M (2010). The future of toxicity testing: a focus on in vitro methods using a quantitative high-throughput screening platform. *Drug Discov Today* 15, 997–1007. [http://dx.doi.org/10.1016/j.drudis.2010.07.007](http://dx.doi.org/10.1016/j.drudis.2010.07.007).